Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 18c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.83), $0.18 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $37.96 million versus the consensus estimate of $27.13 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• MSCI upgrades Bulgaria to Frontier, flags Indonesia and Turkey risks
• Boeing wins $2 billion satellite contract from DoW